Recombinant Human Lymphotoxin-alpha/TNF-beta Protein


Recombinant Human Lymphotoxin-alpha /TNF-beta (Catalog # 211-TBB) induces cytotoxicity in the L-929 mouse fibroblast cell line in the presence of the metabolic inhibitor actinomycin D. The ED50 for this effect is more
1 µg/lane of Recombinant Human Lymphotoxin-alpha /TNF-beta was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a band at 19 kDa.

Product Details

Reactivity HuSpecies Glossary
Applications Bioactivity

Order Details

View Available Formulations

Recombinant Human Lymphotoxin-alpha/TNF-beta Protein Summary

Details of Functionality
Measured in a cytotoxicity assay using L‑929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. Matthews, N. and M.L. Neale (1987) in Lymphokines and Interferons, A Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 221. The ED50 for this effect is 4-20 pg/mL.
E. coli-derived human Lymphotoxin-alpha/TNF-beta protein
Leu35-Leu205, with an N-terminal Met
Accession #
N-terminal Sequence
Protein/Peptide Type
Recombinant Proteins
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.01 EU per 1 μg of the protein by the LAL method.


  • Bioactivity
Theoretical MW
19 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
17-19 kDa, reducing conditions
Read Publications using
211-TBB in the following applications:

Packaging, Storage & Formulations

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in PBS containing at least 0.1% human or bovine serum albumin.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Lymphotoxin-alpha/TNF-beta Protein

  • LT
  • LTA
  • LT-alpha
  • lymphotoxin alpha (TNF superfamily, member 1)
  • Lymphotoxin alpha
  • Lymphotoxinalpha
  • Lymphotoxin-alpha
  • tnfb
  • TNF-beta
  • TNFBlymphotoxin-alpha
  • TNFSF1
  • TNFSF1TNF-beta
  • tumor necrosis factor beta
  • Tumor necrosis factor ligand superfamily member 1


Lymphotoxin-alpha (LT-alpha ), also known as Tumor Necrosis Factor-beta (TNF-beta ), is a member of the TNF Superfamily. Human LT-alpha /TNF-beta is a 22 kDa protein that shares 73% amino acid sequence identity with mouse and rat LT-alpha /TNF-beta (1-3). Secreted LT-alpha forms homotrimers that bind and activate TNF RI/TNFRSF1A, TNF RII/TNFRSF1B, and HVEM/TNFRSF14 (4). LT-alpha /TNF-beta also forms heterotrimers with plasma membrane-localized LT-beta to bind and activate the LT-beta R/TNFRSF3 (4). In addition to its cytotoxic action on tumor cells, LT-alpha /TNF-beta mediates lymph node development, inflammation, and immune function (5-8). LT-alpha /TNF-beta is expressed in activated T- and B lymphocytes and contributes to autoimmune disease (9, 10).

  1. Nedwin, G.E. et al. (1985) J. Cell. Biochem. 29:171.
  2. Gray, P.W. et al. (1984) Nature 312:721.
  3. Kobayashi, Y. et al. (1986) J. Biochem. 100:727.
  4. Warzocha, K. et al. (1995) Eur. Cytokine Netw. 6:83.
  5. McCarthy, D.D. et al.(2006) Immunol. Res. 35:41.
  6. Drutskaya, M.S. et al. (2010) IUBMB Life 62:283.
  7. De Togni, P. et al. (1994) Science 264:703.
  8. Seleznik, G.M. et al. (2014) Cytokine Growth Factor Rev. 25:125.
  9. Mapara, M.Y. et al. (1994) Int. J. Cancer 58:248.
  10. Chiang, E.Y. et al. (2009) Nat. Med. 15:766.

Publications for Lymphotoxin-alpha/TNF-beta (211-TBB)(8)

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 1 application: Bioassay.

Filter By Application
All Applications
Filter By Species
All Species
Showing Publications 1 - 8 of 8.
Publications using 211-TBB Applications Species
M Fellermann, C Huchler, L Fechter, T Kolb, F Wondany, D Mayer, J Michaelis, S Stenger, K Mellert, P Möller, TFE Barth, S Fischer, H Barth Clostridial C3 Toxins Enter and Intoxicate Human Dendritic Cells Toxins (Basel), 2020-09-01;12(9):. 2020-09-01 [PMID: 32883045] (Bioassay, Human) Bioassay Human
TK Darling, PN Mimche, C Bray, B Umaru, LM Brady, C Stone, CE Eboumbou M, TE Lane, LS Ayong, TJ Lamb EphA2 contributes to disruption of the blood-brain barrier in cerebral malaria PLoS Pathog., 2020-01-30;16(1):e1008261. 2020-01-30 [PMID: 31999807] (Bioassay, Human) Bioassay Human
JG Chen, X Liu, M Munshi, L Xu, N Tsakmaklis, MG Demos, A Kofides, ML Guerrera, GG Chan, CJ Patterson, KE Meid, J Gustine, T Dubeau, P Severns, JJ Castillo, ZR Hunter, J Wang, SJ Buhrlage, NS Gray, SP Treon, G Yang BTKCys481Serdrives ibrutinib resistance via ERK1/2, and protects BTKWild-TypeMYD88 mutated cells by a paracrine mechanism Blood, 2018-03-01;0(0):. 2018-03-01 [PMID: 29496671] (Bioassay, Human) Bioassay Human
Sarhan D, Palma M, Mao Y, Adamson L, Kiessling R, Mellstedt H, Osterborg A, Lundqvist A Dendritic cell regulation of NK-cell responses involves lymphotoxin-alpha, IL-12, and TGF-beta. Eur J Immunol, 2015-04-17;45(6):1783-93. 2015-04-17 [PMID: 25773885] (Bioassay, Human) Bioassay Human
Steeland S, Puimege L, Vandenbroucke R, Van Hauwermeiren F, Haustraete J, Devoogdt N, Hulpiau P, Leroux-Roels G, Laukens D, Meuleman P, De Vos M, Libert C Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. J Biol Chem, 2014-12-23;290(7):4022-37. 2014-12-23 [PMID: 25538244] (Bioassay, Human) Bioassay Human
Yaden B, Wang Y, Wilson J, Culver A, Milner A, Datta-Mannan A, Shetler P, Croy J, Dai G, Krishnan V Inhibition of activin A ameliorates skeletal muscle injury and rescues contractile properties by inducing efficient remodeling in female mice. Am J Pathol, 2014-04-01;184(4):1152-66. 2014-04-01 [PMID: 24655377] (Bioassay, Mouse) Bioassay Mouse
Vang , Amanda G, Housley , William, Dong , Hongli, Basole , Chaitali, Ben-Sasson , Shlomo Z, Kream , Barbara, Epstein , Paul M, Clark , Robert B, Brocke , Stefan Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM/ICER: a potential role for Epac. Biochem J, 2013-12-15;456(3):463-73. 2013-12-15 [PMID: 24007532] (Bioassay, Mouse) Bioassay Mouse
Johnson LA, Clasper S, Holt AP, Lalor PF, Baban D, Jackson DG An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J. Exp. Med., 2006-11-20;203(12):2763-77. 2006-11-20 [PMID: 17116732] (Bioassay, Human) Bioassay Human

Reviews for Lymphotoxin-alpha/TNF-beta (211-TBB) (0)

There are no reviews for Lymphotoxin-alpha/TNF-beta (211-TBB). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for Lymphotoxin-alpha/TNF-beta (211-TBB) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Review this Product

Be the first to review our Recombinant Human Lymphotoxin-alpha/TNF-beta Protein and receive a gift card or discount.


Gene Symbol LTA